{
  "id": "2247620401_2",
  "title": "宜联生物 B7-H3 ADC 获 FDA 突破性疗法认定",
  "content": "<div class=\"rich_media_content js_underline_content autoTypeSetting24psection\" id=\"js_content\">\n <section data-mpa-action-id=\"maccl1pf1coy\" data-pm-slice=\"0 0 []\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <a class=\"weapp_image_link js_weapp_entry\" data-miniprogram-appid=\"wx33d4c3735820a33e\" data-miniprogram-applink=\"\" data-miniprogram-imageurl=\"https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vROvmPqd90D6qZZzHhQwNBck2THhGajmUBOiaz7dPLTUw4LGrUazBPtVTYLDmWibvichjicrGCtRyWDg/640?wx_fmt=png&amp;from=appmsg\" data-miniprogram-nickname=\"Insight医药情报助手\" data-miniprogram-path=\"pages/index/index\" data-miniprogram-servicetype=\"0\" data-miniprogram-type=\"image\" style=\"\">\n   <img class=\"rich_pages wxw-img\" data-imgfileid=\"100133179\" data-ratio=\"0.26382978723404255\" data-s=\"300,640\" data-type=\"png\" data-w=\"940\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vROvmPqd90D6qZZzHhQwNBck2THhGajmUBOiaz7dPLTUw4LGrUazBPtVTYLDmWibvichjicrGCtRyWDg/640?wx_fmt=png&amp;from=appmsg\" type=\"block\"/>\n  </a>\n </section>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span data-mpa-action-id=\"mc9vrnpxlsn\" leaf=\"\" style=\"font-size: 15px;\">\n   6 月 23 日，宜联生物宣布\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    B7-H3 靶向 ADC\n   </span>\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    YL201\n   </span>\n   获美国 FDA 授予突破性疗法认定，用于治疗\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    小细胞肺癌\n   </span>\n   <span style=\"color: rgb(136, 136, 136);font-weight: bold;\" textstyle=\"\">\n    （SCLC）\n   </span>\n   。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-bottom: 8px;\">\n  <img class=\"rich_pages wxw-img\" data-croporisrc=\"https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vylr4uh8mWSaXiaic1Msrq15TnuSYpFgm2eY6meKz2ZCiacemh3zgA0uztT0MiaOnkKTVxgk7pzc8FAg/0?wx_fmt=png&amp;from=appmsg\" data-cropx2=\"794\" data-cropy2=\"125.00692041522491\" data-imgfileid=\"100136750\" data-ratio=\"0.1574307304785894\" data-s=\"300,640\" data-type=\"png\" data-w=\"794\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_jpg/lVFg8Ny0F8vylr4uh8mWSaXiaic1Msrq15hHwSw4tfTQo25oPnWEPibIVmJzYdDWoCtsQtFjclUmC0COPHVE2hy6g/640?wx_fmt=jpeg\" style=\"width: 1080px;height: 91px;\" type=\"block\"/>\n </section>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;text-align: center;\">\n  <span data-pm-slice=\"0 0 []\" style='color: rgb(178, 178, 178);font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 12px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 1px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;'>\n   <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;text-align: center;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"},\"node\",{\"tagName\":\"span\",\"attributes\":{\"style\":\"color: rgb(178, 178, 178);font-family: mp-quote, \\\"PingFang SC\\\", system-ui, -apple-system, BlinkMacSystemFont, \\\"Helvetica Neue\\\", \\\"Hiragino Sans GB\\\", \\\"Microsoft YaHei UI\\\", \\\"Microsoft YaHei\\\", Arial, sans-serif;font-size: 12px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 1px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;\",\"data-pm-slice\":\"0 0 []\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\">\n    截图来源：企业官微\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   B7-H3 在多种恶性肿瘤的分化和起始细胞上过表达，但在正常组织中的表达有限，具备针对多癌种开发 ADC 药物的潜力。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   YL201 是一款基于宜联生物医药自主创新 TMALIN®技术平台开发的靶向 B7-H3 的 ADC 药物。2024 年 10 月，YL201 已被 CDE 纳入突破性治疗，用于治疗经初始含铂治疗失败的复发性小细胞肺癌。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   目前，YL201 项目正在全球范围内开展多项临床研究。其中，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    小细胞肺癌、鼻咽癌适应症在中国已进入临床 III 期研究阶段\n   </span>\n   。同时\n  </span>\n  <span data-mpa-action-id=\"mc9vrnpxlsn\" data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   宜联\n  </span>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   也在开展多项\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   YL201\n  </span>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   单药及联用试验，探索其在多种实体瘤的治疗潜力。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   去年 ESMO 大会上，宜联首次披露了 YL201 的 I 期临床数据。其中，广泛期小细胞肺癌\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （ES-SCLC）\n   </span>\n   队列共有 72 例患者可评估疗效，他们既往全部接受过含铂化疗，95% 接受过抗 PD-(L)1 治疗。\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    患者 ORR 为 68.1%，mPFS 为 6.2 个月\n   </span>\n   。在脑转移患者中，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    YL201 的疗效与整体人群可比，ORR 为 52.2%，mPFS 为 5.3 个月\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   2025 年 3 月，宜联又在 2025 年欧洲肺癌大会\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （ELCC）\n   </span>\n   年会上公布了 YL201 在肺癌患者中的颅内疗效数据。此次报告数据来自于在中、美开展的 I 期临床剂量递增和剂量扩展研究\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （NCT05434234 &amp; NCT06057922）\n   </span>\n   。截至 2024 年 11 月 15 日，该项研究共入组 329 例晚期实体瘤患者，其中 29 例肺癌患者存在基线脑转移，包括 21 例小细胞肺癌患者和 8 例野生型非小细胞肺癌患者。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   有效性方面，在 29 例存在基线脑转移病灶\n   <span style=\"color: #b2b2b2;\" textstyle=\"\">\n    （靶病灶或非靶病灶）\n   </span>\n   的肺癌患者中，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    确认的颅内客观缓解率\n   </span>\n   <span style=\"color: #b2b2b2;font-weight: bold;\" textstyle=\"\">\n    （ic-ORR）\n   </span>\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    为 17.2%\n   </span>\n   ，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    颅内疾病控制率\n   </span>\n   <span style=\"color: #b2b2b2;font-weight: bold;\" textstyle=\"\">\n    （ic-DCR）\n   </span>\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    为 93.1%\n   </span>\n   。\n  </span>\n </p>\n <ul class=\"list-paddingleft-1\" style=\"list-style-type: disc;\">\n  <li>\n   <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n    <span leaf=\"\" style=\"font-size: 15px;\">\n     对于 13 例存在基线脑部靶病灶的患者，确认的 ic-ORR 为 30.8%，ic-DCR 为 100.0%。其中，小细胞肺癌和野生型非小细胞肺癌亚组人群的 ic-ORR 分别为 30.0% 和 33.3%。\n    </span>\n   </p>\n  </li>\n  <li>\n   <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n    <span leaf=\"\" style=\"font-size: 15px;\">\n     对于既往 6 个月内未接受过脑部放疗的患者，YL201 同样显示出良好的颅内疗效，确认的 ic-ORR 为 57.1%，ic-DCR 为 100.0%。\n    </span>\n   </p>\n  </li>\n </ul>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;margin-top: 24px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在 29 例存在基线脑转移\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （靶病灶或非靶病灶）\n   </span>\n   <span style=\"color: rgb(0, 0, 0);\" textstyle=\"\">\n    的肺\n   </span>\n   癌患者中\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    ，中位 ic-PFS 达到了 6.3 个月\n   </span>\n   ，其中\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    小细胞肺癌亚组人群的中位 ic-PFS 达到了 6.2 个月\n   </span>\n   ，野生型非小细胞肺癌亚组人群的\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    中位 ic-PFS 达到了 7.4 个月\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span data-mpa-action-id=\"mc9vrnpx1azi\" leaf=\"\" style=\"font-size: 15px;\">\n   在显示出良好颅内疗效的同时，YL201 的中枢神经系统毒性却相当低。在接受治疗的全部 329 例患者中，只有 0.9% 的患者报告了≥3 级的神经系统疾病。\n  </span>\n </p>\n <section data-mpa-action-id=\"maccl1pfuvy\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;text-align: left;'>\n  <span style=\"outline: 0px;font-size: 12px;visibility: visible;color: rgb(163, 163, 163);\">\n   <strong style=\"outline: 0px;letter-spacing: 0.544px;visibility: visible;\">\n    <span leaf=\"\">\n     封面来源：\n    </span>\n   </strong>\n   <span style='outline: 0px;visibility: visible;font-family: -apple-system, system-ui, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;'>\n    <span leaf=\"\">\n     企业 Logo\n    </span>\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"maccl1pfdkf\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;text-align: left;'>\n  <span style=\"outline: 0px;font-size: 15px;visibility: visible;color: rgb(178, 178, 178);\">\n   <strong style=\"outline: 0px;letter-spacing: 0.544px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     免责声明：\n    </span>\n   </strong>\n   <span style=\"outline: 0px;letter-spacing: 0.544px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。\n    </span>\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"maccl1pf1fu2\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;text-align: left;'>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </section>\n <section data-mpa-action-id=\"maccl1pf8hh\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;'>\n  <span style=\"outline: 0px;font-size: 12px;color: rgb(178, 178, 178);visibility: visible;\">\n   <strong style=\"outline: 0px;visibility: visible;\">\n    <span leaf=\"\">\n     编辑\n    </span>\n   </strong>\n   <span leaf=\"\">\n    ：馨药\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"maccl1pfmj\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;'>\n  <span style=\"outline: 0px;color: rgb(178, 178, 178);visibility: visible;\">\n   <strong style=\"outline: 0px;visibility: visible;\">\n    <span style=\"outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      PR 稿对接\n     </span>\n    </span>\n   </strong>\n   <span style=\"outline: 0px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     ：微信 insightxb\n    </span>\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"maccl1pfzg9\" style='margin-right: 8px;margin-bottom: 24px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;'>\n  <span style=\"outline: 0px;color: rgb(178, 178, 178);visibility: visible;\">\n   <strong style=\"outline: 0px;visibility: visible;\">\n    <span style=\"outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      投稿\n     </span>\n    </span>\n   </strong>\n   <span style=\"outline: 0px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     ：微信 insightxb；邮箱 insight@dxy.cn\n    </span>\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"maccl1pf149a\" nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;margin-bottom: 0px;\">\n  <img class=\"rich_pages wxw-img\" data-imgfileid=\"100133180\" data-ratio=\"0.6319148936170212\" data-s=\"300,640\" data-type=\"png\" data-w=\"940\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vROvmPqd90D6qZZzHhQwNBzyf7pyZ00Jj17v3UdI4lHwH4Wr619icjjBYhbcBFjPCc9Jkib4472Piag/640?wx_fmt=png&amp;from=appmsg\" type=\"block\"/>\n </section>\n <section>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </section>\n <p style=\"display: none;\">\n  <mp-style-type data-value=\"3\">\n  </mp-style-type>\n </p>\n</div>\n",
  "publish_time": 1750731170,
  "mp_id": "MP_WXS_3975077766",
  "pic_url": "https://mmbiz.qlogo.cn/mmbiz_jpg/lVFg8Ny0F8sH2wHNSYfp8MiaIPraavfnHh4ludoibVpAP6r4yS57xdsA5PhPQpnwsJ93iaXtDib7g4UBeP5dBotOGA/0?wx_fmt=jpeg",
  "mp_name": "Insight数据库"
}